Table 1

Incremental cost-effectiveness measures (model-based analysis)

Time horizonInterventionCost (£)Δ Cost (£)QALYΔQALYICER (Δ Cost/ΔQALY) (£)NMBProbability cost-effective at Rc
0£10 000£20 000£50 000
EQ-5D-based QALYs
2-year time horizonTrabeculectomy343621061.230.0447 66321 1080.10.260.390.5
Medication13301.1822 3300.90.740.610.5
10-year time horizonTrabeculectomy542123623.720.1713 91169 0240.080.40.590.73
Medication30593.5567 9900.920.60.410.27
Lifetime horizonTrabeculectomy727326875.920.289679111 0520.080.50.730.85
Medication45865.64108 1870.920.50.270.15
HUI-based QALYs
2-year time horizonTrabeculectomy343621061.170.0539 72419 9780.090.290.40.52
Medication13301.1221 0240.910.710.60.48
10-year time horizonTrabeculectomy542123623.580.2210 50666 1150.10.50.650.75
Medication30593.3563 9800.90.50.350.25
Lifetime horizonTrabeculectomy727326875.700.387016106 7790.060.620.810.88
Medication45865.32101 8060.940.380.190.12
GUI-based QALYs
2-year time horizonTrabeculectomy343621061.240.01147 24721 3020.090.180.280.41
Medication13301.2323 1220.910.820.720.59
10-year time horizonTrabeculectomy542123623.730.124 17969 2690.080.260.440.6
Medication30593.6469 6770.920.740.560.4
Lifetime horizonTrabeculectomy727326875.920.1616 805111 1650.060.320.550.74
Medication45865.76110 6550.940.680.450.26
  • EQ-5D, EuroQol Five Dimension; GUI, glaucoma utility index; HUI, health utilities index; ICER, incremental cost-effectiveness ratio; NMB, net monetary benefit; QALY, quality-adjusted life-year; Rc, ceiling ratio of willingness to pay per QALY gained.